

# CONTENTS

<b>Contributors</b>	<b>xi</b>
<b>Preface</b>	<b>xiii</b>
<b>17 Bioactive Molecules in Medicinal Plants: A Perspective on Their Therapeutic Action</b>	<b>1</b>
<i>S. C. Taneja and G. N. Qazi</i>	
17.1 Introduction,	1
17.2 Evolutionary Relationships Among Plants and Humans,	2
17.3 Traditional Wisdom,	3
17.4 Unique Libraries for Plants,	4
17.5 Drugs and Bioactive Molecules from Plants,	6
17.6 Synergism in Herbal Formulations,	36
17.7 Interactions Between Modern Drugs and Natural Products,	37
17.8 Bioavailability and Bioefficacy Enhancers,	38
17.9 Combination Therapies in Modern Drugs,	39
17.10 Role of Developments in Technologies and Analytical Tools,	40
17.10.1 Developments in Separation Technologies,	40
17.10.2 Developments in Combined Techniques and Advanced Technologies,	41
17.10.3 Molecular Farming and Bioengineering of Medicinal Plants,	42
17.10.4 High-Throughput Screening of Natural Products,	42
17.11 Herbal Medicine: The Best Possible Route to Health Care,	43
References,	44

<b>18</b>	<b>Natural Products as an Inspiration for the Discovery of New High-Throughput Chemical Synthesis Tools</b>	<b>51</b>
	<i>Steven V. Ley, Ian R. Baxendale, Deborah A. Longbottom, and Rebecca M. Myers</i>	
	18.1 Introduction, 51	
	18.2 Solid-Supported Reagents as Tools in Natural Product Synthesis, 52	
	18.3 Multistep Use of Supported Reagents in Natural Product Synthesis, 57	
	18.4 Conclusions, 85	
	References, 86	
<b>19</b>	<b>Insulin Sensitizers: Emerging Therapeutics</b>	<b>91</b>
	<i>Braj B. Lohray and Vidya B. Lohray</i>	
	19.1 Introduction, 91	
	19.2 Therapeutic Interventions, 92	
	19.3 Discovery of Insulin Sensitizers, 92	
	19.4 Journey Toward New Drugs, 94	
	19.5 Conclusions, 116	
	References, 117	
<b>20</b>	<b>Criteria for Industrial Readiness of Chiral Catalysis Technology for the Synthesis of Pharmaceuticals</b>	<b>121</b>
	<i>Raymond McCague and Ian C. Lennon</i>	
	20.1 Introduction, 121	
	20.2 Criteria for Technology Readiness, 122	
	20.3 Examples of Industrially Ready Chiral Catalytic Technologies and Their Application, 124	
	20.3.1 Lipase Bioresolution: Ethyl 3-Amino-3-Phenylpropionate, 124	
	20.3.2 Aminoacylase Bioresolution of <i>N</i> -Acylamino Acids, 126	
	20.3.3 Asymmetric Hydrogenation of Prochiral Olefins by Rhodium–DuPhos Catalysts, 127	
	20.3.4 Asymmetric Hydrogenation of Prochiral Ketones by Ruthenium–Biphosphine–Diamine Catalysts, 129	
	20.3.5 Asymmetric Hydroformylation with Rhodium–Phosphite Catalysts, 132	
	20.3.6 Asymmetric Allylic Substitution with Palladium-Based Catalysts, 133	
	20.4 How Industrially Ready Technology Can Deliver Commercial Advantages, 136	
	20.5 Conclusions, 138	
	References, 138	
<b>21</b>	<b>Enantioselective Synthesis of Propargyl Alcohols as Multifunctional Synthons</b>	<b>141</b>
	<i>J. S. Yadav and S. Chandrasekhar</i>	
	21.1 Introduction, 141	
	21.2 Asymmetric Reduction of Prochiral $\alpha$ , $\beta$ -Alkynyl Ketones, 142	

21.3	Addition of Acetylenic Anion to Carbonyl Carbon,	148
21.4	Desymmetrization and Enzymatic Strategies for Chiral Propargyl Alcohol Synthesis,	155
21.5	$\beta$ -Elimination Strategy and Miscellaneous Approaches,	157
21.6	Conclusions,	159
	References,	159
<b>22</b>	<b>Carbohydrates: From Chirons to Mimics</b>	<b>161</b>
	<i>G. V. M. Sharma and Palakodety Radha Krishna</i>	
22.1	Introduction,	161
22.2	Synthetic Strategies for C-Glycosides,	162
22.3	Synthetic Strategies for Carbon-Linked Disaccharides and Pseudosaccharides,	168
	References,	178
<b>23</b>	<b>Meeting the Challenges of Process Development and Scale-up of Active Pharmaceutical Ingredients</b>	<b>181</b>
	<i>Yatendra Kumar and B. Vijayaraghavan</i>	
23.1	Introduction,	181
23.1.1	Drug Development in the Pharmaceutical Industry,	181
23.1.2	Challenges in Developing and Scaling Up Chemical Processes,	182
23.2	Process Development Cycle,	183
23.2.1	Stage I. Literature Survey and Analysis: Preparing the Blueprint,	184
23.2.2	Stage II. Process Development: Laying the Foundation,	189
23.2.3	Stage III. Process Optimization: Constructing the Building Brick by Brick,	192
23.2.4	Stage IV. Process Validation: Finishing Touches—Grinding and Polishing,	195
23.2.5	Stage V. Process Scale-up: The Moment of Truth,	196
23.3	Conclusions,	198
	References,	198
<b>24</b>	<b>Importance of Polymorphs and Salts in the Pharmaceutical Industry</b>	<b>201</b>
	<i>Bipin Pandey, Vidya B. Lohray, and Braj B. Lohray</i>	
24.1	Introduction,	201
24.2	Drug Discovery and Development,	202
24.3	Salt Selection,	204
24.4	Pseudopolymorphs,	206
24.4.1	Hydrates,	206
24.4.2	Solvates,	207
24.4.3	Amorphous Solids,	208
24.5	Analytical Tools,	208
24.6	Process Development,	210
24.7	Formulation Development,	212
24.8	Regulatory Concerns,	213

24.9	Patent Implications, 213	
24.10	Predictions and Uncertainties, 214	
24.11	Conclusions, 215	
	References, 216	
<b>25</b>	<b>Role of Outsourcing in Drug Manufacture</b>	<b>219</b>
	<i>Peter Pollak</i>	
25.1	Introduction, 219	
25.2	Outsourcing in the Pharmaceutical Industry, 220	
	25.2.1 Outsourcing of Chemical Manufacturing, 222	
	25.2.2 Outsourcing of Research and Development, 231	
	References, 232	
<b>26</b>	<b>Regulation-Driven Process Chemistry</b>	<b>233</b>
	<i>Shrikant V. Kulkarni</i>	
26.1	Introduction, 233	
26.2	Chemical Industry Regulatory Guidelines, 233	
26.3	Manufacturing Techniques in Process Chemistry, 237	
26.4	Effects of Pesticide Industry Regulation, 239	
26.5	Efforts at Denitrification, 241	
26.6	Evolution to Green Chemistry, 247	
	References, 248	
<b>27</b>	<b>Chemical Process Scale-up Tools: Mixing Calculations, Statistical Design of Experiments, and Automated Laboratory Reactors</b>	<b>251</b>
	<i>Andrei A. Zlota</i>	
27.1	Chemical Process Scale-up Challenges, 251	
27.2	Case Study: Development of an Active Pharmaceutical Ingredient Crystallization Process, 253	
27.3	Case Study: Determination of a Scale-up Factor for the Bourne III Reactive System, 256	
27.4	Conclusions, 261	
	References and Notes, 262	
<b>28</b>	<b>Library Quality Metrics</b>	<b>265</b>
	<i>Richard L. Wife and Johan Tijhuis</i>	
28.1	Drug Discovery and Development, 265	
28.2	Compound Libraries, 267	
28.3	Library Metrics, 268	
	28.3.1 Chemical Structure, 268	
	28.3.2 Druglikeness, 269	
	28.3.3 Novelty, 270	
	28.3.4 Diversity, 272	
	28.3.5 Numbers and Costs, 273	
	28.3.6 Analogs, 274	

28.3.7 Resupply, 275	
28.3.8 Compound Purity, 275	
28.3.9 Compound Stability, 276	
28.3.10 Compound Solubility, 276	
28.3.11 Serendipity, 276	
28.4 Conclusions, 277	
<b>29 Tying a GABA from Copenhagen to Chicago: The Chemistry of Tiagabine</b>	<b>279</b>
<i>Mukund S. Chorghade, Mahendra N. Deshpande, and Richard J. Pariza</i>	
29.1 Introduction, 279	
29.2 Synthesis of Symmetrical Analogs: Tiagabine, 285	
29.3 Synthesis of Unsymmetrical Analogs: Desmethyltiagabine, 288	
29.3.1 Syntheses of Regioisomers of Tiagabine, 291	
29.3.2 Human Metabolite of Tiagabine: 5-Hydroxytiagabine, 292	
29.4 Attempted Biomimetic Synthesis of 5-Hydroxytiagabine, 296	
29.5 Oxidative Degradation Products of Tiagabine, 298	
29.5.1 Dihydroxytiagabine, 298	
29.5.2 Ketotiagabine, 299	
29.6 Metalloporphyrins as Chemical Mimics of Cytochrome P450 Systems, 301	
29.6.1 Oxometalloporphyrins, 302	
29.6.2 Synthesis of the Sterically Protected and Electronically Activated Metalloporphyrins, 303	
29.6.3 Application of the Methodology to Selected Drugs, 303	
References, 306	
<b>30 Building Contract Research Businesses Based on Integration of Basic and Applied Research</b>	<b>309</b>
<i>Mukund S. Chorghade, Mukund K. Gurjar, C. V. Ramana, and Sreenivas Punna</i>	
30.1 Introduction, 309	
30.2 Solving Real-World Problems, 312	
30.2.1 Synthesis of $\beta$ -Blockers, 315	
30.2.2 Ring-Closing Metatheses as a Pathway to Chiral Compounds, 319	
30.3 Synthesis of Pharmaceutically Relevant Chiral Tetrahydrofurans, 323	
30.3.1 Discovery Route, 325	
30.3.2 Alternative Strategies for Synthesis of Compounds 130 to 133 Based on C-Alkynyl Furan Derivatives, 334	
30.4 Drugs for the Treatment of Skin Disorders, 339	
30.4.1 Discovery Synthesis of Compound 229, 340	
30.4.2 Process Innovation for Compound 229: Systematic Investigation, 341	
30.4.3 Alternative Routes for Compound 229, 346	
30.5 Conclusions, 350	
References, 350	

<b>31 Principles and Practice of Clinical Drug Development</b>	<b>355</b>
<i>Colin Scott</i>	
31.1 Introduction, 355	
31.2 History of Ethical Medical Research, 356	
31.3 History of the Regulation of Medical Research, 360	
31.4 Preclinical Development, 364	
31.5 Clinical Development, 369	
31.6 Conclusions, 374	
<b>Index</b>	<b>375</b>